Low molecular weight heparin versus no treatment in women with previous severe pregnancy complications and placental findings without thrombophilia
- 1 March 2011
- journal article
- research article
- Published by Wolters Kluwer Health in Blood Coagulation & Fibrinolysis
- Vol. 22 (2) , 123-126
Abstract
Low molecular weight heparin (LMWH) treatment has been recommended for pregnant women with previous adverse pregnancy and who were diagnosed as having a thrombophilia. We now examined the effect of LMWH on pregnant women without thrombophilias who had severe pregnancy complications and placental vasculopathy in an earlier pregnancy. Seventy-two women with a history of severe preeclampsia, fetal growth restriction (FGR) less than fifth percentile, severe placental abruption and/or stillbirth after 20 weeks, whose thrombophilia workup was negative, were enrolled. Placental vasculopathy was defined as villous infarcts, fibrinoid necrosis of decidual vessels, fetal vessel thrombosis, evidence of placental abruption and perivillous fibrin deposition. The study group consisted of 32 pregnant women who were treated with LMWH and 40 pregnant women who were not treated with LMWH (control group) in their ensuing pregnancy in our institution between 2003 and 2007. The incidences of severe preeclampsia, FGR, placental abruption and stillbirth in the previous pregnancies were similar for both groups. The incidences of severe preeclampsia and placental abruption in the study group in the index pregnancy were significantly lower than the control group (3.13 versus 20%, P = 0.03; and 0 versus 15%, P = 0.03, respectively). The respective incidence of FGR was 6.25 versus 22.5%, and of overall adverse outcome was 9.4 versus 60% (P = 0.001). Treatment with LMWH may reduce the rate of the recurrence of severe pregnancy complications and significant placental vasculopathy in women without thrombophilias.Keywords
This publication has 23 references indexed in Scilit:
- Neoventa Medical ABJournal of Perinatal Medicine, 2009
- Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trialJournal of Thrombosis and Haemostasis, 2009
- The placenta in pre-eclampsia and intrauterine growth restrictionJournal of Clinical Pathology, 2008
- Antithrombotic prophylaxis during pregnancy in women with deficiency of natural anticoagulantsBlood Coagulation & Fibrinolysis, 2008
- Prophylaxis of Recurrent Preeclampsia: Low-Molecular-Weight Heparin plus Low-Dose AspirinversusLow-Dose Aspirin AloneHypertension in Pregnancy, 2006
- Thrombophilia in pregnancy: a systematic reviewBritish Journal of Haematology, 2005
- Low-Molecular-Weight Heparin Lowers the Recurrence Rate of Preeclampsia and Restores the Physiological Vascular Changes in Angiotensin-Converting Enzyme DD WomenHypertension, 2005
- Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorderBlood, 2004
- Low-Molecular-Weight Heparin for the Prevention of Obstetric Complications in Women with ThrombophiliasHypertension in Pregnancy, 2001
- Prevention of Preeclampsia with Heparin and Antiplatelet Drugs in Women with Renal DiseaseAustralian and New Zealand Journal of Obstetrics and Gynaecology, 1995